MINK THERAPEUTICS INC
Mink Therapeutics, Inc. (INKT) is a small‑capitalisation biotechnology company (market cap about $67m) focused on developing cell‑based immunotherapies and related immune‑oncology approaches. Investors should know it is an early‑stage, research‑driven business: valuation tends to reflect scientific progress, clinical or preclinical milestones, partnerships and the ability to raise capital rather than steady revenues. That profile creates potential upside if programmes advance, but also significant downside from trial setbacks, regulatory hurdles, manufacturing complexity and financing risk. Shares can be highly volatile and subject to dilution from future fundraising. This summary is educational only and not personal investment advice; it is intended to help you understand the company’s business and risks. Suitable investors are typically those comfortable with long time horizons, high uncertainty and the possibility of loss. Always consider seeking independent financial advice before investing.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MINK Therapeutics' stock with a target price of $8, suggesting growth potential.
Financial Health
Mink Therapeutics is producing solid cash flow per share, indicating good financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring INKT
MASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: September 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Cell therapy focus
Develops cell‑based immunotherapies and immune approaches; scientific progress can influence value, though clinical outcomes remain uncertain.
Early-stage potential
Small market cap can offer upside if milestones succeed, but shares are often volatile and future fundraising may dilute holders.
Regulatory pathway matters
Advancement depends on trial results and approvals across jurisdictions; commercialisation requires capital, manufacturing and partnerships.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.